uploads///Afinitor

How Did Novartis’s Affinitor, Exjade, and Tafinlar+Mekinist Perform in 2017?

By

Mar. 29 2018, Updated 7:34 a.m. ET

Afinitor revenue trends

In 4Q17, Novartis’s (NVS) Afinitor generated revenues of $407 million compared to $391 million in 4Q16, which reflected ~4% growth on a year-over-year (or YoY) basis and ~5% growth quarter-over-quarter. In fiscal 2017, Afinitor generated revenues of $1.5 billion, which reflected ~1% growth on a YoY basis.

Afinitor witnessed slight growth due to competitive pressures in the marketplace. The growth in the use of Afinitor for neuroendocrine tumor and tuberous sclerosis complex primarily led to the revenue growth of the drug. In the marketplace, Afinitor’s peers include Pfizer’s (PFE) Ibrance, AstraZeneca’s (AZN) Faslodex, and Lynparza.

Article continues below advertisement

Exjade/Jadenu revenue trends

In 4Q17, Exjade/Jadenu generated revenues of $281 million, which reflected ~19% growth on a year-over-year (or YoY) basis and 6% growth quarter-over-quarter. In fiscal 2017, Exjade/Jadenu generated revenues of $1.1 billion compared to $956 million in 2016, which reflected ~11% growth on a YoY basis.

The growth in sales in the US market and increased uptake of Exjade Film-Coated Tablet (or FCT) primarily attributed to the revenue growth of Exjade in 2017.

Tafinlar+Mekinist revenue trends

In 4Q17, Tafinlar+Mekinist generated revenues of $246 million, which is ~38% growth on a YoY basis and 10% growth quarter-over-quarter. In fiscal 2017, Tafinlar+Mekinist generated revenues of $873 million compared to $672 million in 2016, which reflected ~30% growth on a YoY basis.

Increased demand in the US market and new launches in the Europe market primarily pushed the revenue growth of Tafinlar+Mekinist in 2017. Tafinlar+Mekinist combination therapy finds its use in the treatment of BRAF V600E/K mutation-positive unresectable or metastatic melanoma. In the marketplace, Tafinlar+Mekinist competes with Roche’s (RHHBY) Cotellic and Zelboraf.

Advertisement

More From Market Realist

    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.